Israel’s CytoReason, S. Korea’s Helixrus partner on machine learning for drug development
CytoReason Expands Its Reach in Asia, Forging Commercial Alliance with Helixrus to Leverage Machine Learning in Drug Development for Korean Drugmakers
Poolbeg signs deal with Cytoreason on influenza drug development
Poolbeg Pharma signs first of its kind AI deal with CytoReason
Pfizer, CytoReason extend AI pact after immune system success
Why Big Pharma is partnering with startups as it becomes more data-driven
CytoReason and Pfizer Extend Collaboration to Leverage Machine Learning in Drug Development
Pfizer re-ups CytoReason collab applying AI disease models to drug development
The CytoReason Platform
Indication selection for anti-PDx combination therapy In collaboration with big pharma
